oral DNA-PK inhibitor - AstraZeneca

oral DNA-PK inhibitor

Ph. I/II candidate for advanced tumors

from screening for selectivity vs. PI3Ka

Mol. Cancer Ther.


Context. AZD7648 (AstraZeneca) is an oral DNA-PK inhibitor. DNA-PK, ATR, and ATM are all kinases involved in DNA damage repair and have been of significant recent interest due to…

 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.